Your browser doesn't support javascript.
loading
Response to Immunotherapy in Sclerosing Epithelioid Fibrosarcoma: Case Report and Literature Review.
Koerner, Anna S; Zhou, Maggie; Brook, Ashley; Yoon, Sam S; Ganjoo, Kristen N.
Afiliação
  • Koerner AS; Surgical Oncology, Surgery, Columbia University Irving Medical Center, New York, USA.
  • Zhou M; Hematology and Medical Oncology, Stanford University School of Medicine, Stanford, USA.
  • Brook A; Hematology and Medical Oncology, Stanford University School of Medicine, Stanford, USA.
  • Yoon SS; Surgical Oncology, Surgery, Columbia University Irving Medical Center, New York, USA.
  • Ganjoo KN; Hematology and Medical Oncology, Stanford University School of Medicine, Stanford, USA.
Cureus ; 15(12): e50967, 2023 Dec.
Article em En | MEDLINE | ID: mdl-38259411
ABSTRACT
Sclerosing epithelioid fibrosarcoma (SEF) is an extremely rare subtype of sarcoma that appears histologically low-grade yet usually has a clinically aggressive course with a high rate of local recurrence and distant metastasis. However, these recurrences and metastases often occur years after initial treatment. Metastases can be to the lung as well as extra-pulmonary sites. In this case report, we discuss a patient who developed SEF in the deep soft tissue with metastases. This patient underwent checkpoint inhibitor therapy, with disease response. Thus, SEF is a sarcoma subtype with a unique tumor biology, and immunotherapy may be a promising avenue for treatment.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article